Have any questions? 706-721-6582 or cts@augusta.edu
- Pilot Study of Daratumumab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD) in Newly Diagnosed Multiple Myeloma Patients with Renal Failure
Clinical Trial
Pilot Study of Daratumumab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD) in Newly Diagnosed Multiple Myeloma Patients with Renal Failure
This is a study enrolling patients with newly diagnosed multiple myeloma who have new onset renal failure. The study plans for 50% of all participants enrolled to be African American. All participants will be given induction treatment of Daratumumab in combination with Bortezomib, Cyclophosamide, and Dexamethasone (Dara-CyBord) after receiving an autologous stem cell transplant.
Eligibility Criteria
- Male or female, aged 18-80 years. Subjects with a new diagnoisis of multiple myeloma with renal insufficiency within 3 months of this study. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
RESEARCH. INNOVATION. DISCOVERY.